NIFTY 50 22795.9 ▼ (0.51%)
NIFTY NEXT 50 60466.8 ▼ (0.94%)
NIFTY 100 23274.05 ▼ (0.59%)
NIFTY MIDCAP 100 50486.2 ▼ (1.32%)
NIFTY SMALLCAP 100 15636.9 ▼ (0.7%)
NIFTY SMALLCAP 250 14683.4 ▼ (0.57%)
NIFTY MIDCAP SELECT 11198.9 ▼ (1.69%)
NIFTY TOTAL MARKET 11634.25 ▼ (0.67%)
NIFTY BANK 48981.2 ▼ (0.72%)
SENSEX 75311.06 ▼ (0.56%)
BSE BANKEX 55718.18 ▼ (0.82%)

Suven Life Sciences ‘s Q3 2024-25 Latest News: Revenue Decreases by 34.31% Year-on-Year

January 24, 2025January 24, 2025| adminadmin| 0 Comments| 7:25 pm
[fetch_key]
Categories:

Share the post "Suven Life Sciences ‘s Q3 2024-25 Latest News: Revenue Decreases by 34.31% Year-on-Year"

  • Facebook
  • LinkedIn
  • X
  • Tumblr
  • WhatsApp
  • TelegramTelegram
  • Email

Highlights

🔹 The presented financial data is Consolidated to provide a comprehensive overview of the company performance.
🔹 Sales over the Year and quarter: The company’s sales declined by -34.31 % over the year, decrease in net sales/revenue by -37.43 %.
🔹 Income over the Year and quarter: There has been decline in other income over the past year which is -73.11 %, Marginal decrease of -59.59% in other income during this quarter.
🔹 Profit over the Year and quarter: Challenges in sustaining profitability for Suven Life Sciences Limited. Profit dropped by -6.34 % Year to Year, Suven Life Sciences Limited’s profitability dropped by -21.2 % Quarter to Quarter.
🔹 EPS over the Year and quarter: EPS declined by -6.77 % Year to Year. EPS decreased by -21.15 % in previous quarter. Analysis needed for shareholder value.

This report meticulously dissects the performance of Suven Life Sciences Limited, offering a panoramic view of its operational success and challenges. It delves into a variety of financial metrics, such as revenue growth, profit margins, and shareholder returns, juxtaposed against the backdrop of broader economic conditions and sector-specific trends. The analysis further explores the investor community’s perception and expectations, which influence the stock’s volatility and potential returns. By providing a forecast based on quantitative analyses and market sentiment, the report aims to outline the potential risks and rewards, guiding investors toward making strategic, data-driven investment choices.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 2.451 Cr Rs. 2.573 Cr Rs. 1.61 Cr -37.43 % -34.31 %
Expenses Rs. 48.64 Cr Rs. 54.78 Cr Rs. 40.81 Cr -25.5 % -16.1 %
Operating Profit Rs. -46.19 Cr Rs. -52.21 Cr Rs. -39.2 Cr + 24.92 % + 15.13 %
OPM % -1884.54 % -2029.15 % -2434.78 % -405.63 % -550.24 %
Other Income Rs. 6.066 Cr Rs. 4.036 Cr Rs. 1.631 Cr -59.59 % -73.11 %
Interest Rs. 0.04 Cr Rs. 0.02 Cr Rs. 0.01 Cr -50 % -75 %
Depreciation Rs. 1.6 Cr Rs. 1.46 Cr Rs. 1.53 Cr + 4.79 % -4.38 %
Profit before tax Rs. -41.76 Cr Rs. -49.65 Cr Rs. -39.11 Cr + 21.23 % + 6.35 %
Tax % -0 % -0 % -0 % 0 % 0 %
Net Profit Rs. -41.77 Cr Rs. -49.64 Cr Rs. -39.12 Cr + 21.19 % + 6.34 %
EPS in Rs Rs. -1.92 Rs. -2.27 Rs. -1.79 + 21.15 % + 6.77 %


Today, we’re looking at Suven Life Sciences Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a significant year-over-year sales decline of -34.31 %. However, it did see a marginal slip of -37.43 % from the previous quarter. Expenses decreased slightly by -25.5 % quarter-on-quarter, aligning with the annual decline of -16.1 %. Operating profit, while up 15.13 % compared to last year, faced a quarter-on-quarter increase of 24.92 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -550.24 %, but a shrinkage of -405.63 % sequentially. Other income fell by -59.59 % compared to the last quarter, despite an annual decline of -73.11 %. Interest expenses dropped significantly by -50 % from the previous quarter, yet the year-over-year decrease remains at a moderate -75 %. Depreciation costs climbed by 4.79 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -4.38 %. Profit before tax grew annually by 6.35 % but saw an increase from the preceding quarter by 21.23 %.
Net profit rose by 6.34 % year-on-year but experienced a 21.19 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 6.77 % but a quarterly rise of 21.15 %. In summary, Suven Life Sciences Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 2.451 Cr Rs. 2.573 Cr Rs. 1.61 Cr -37.43 % -34.31 %
Expenses Rs. 48.64 Cr Rs. 54.78 Cr Rs. 40.81 Cr -25.5 % -16.1 %
Operating Profit Rs. -46.19 Cr Rs. -52.21 Cr Rs. -39.2 Cr + 24.92 % + 15.13 %
Net Profit Rs. -41.77 Cr Rs. -49.64 Cr Rs. -39.12 Cr + 21.19 % + 6.34 %
EPS in Rs Rs. -1.92 Rs. -2.27 Rs. -1.79 + 21.15 % + 6.77 %


In reviewing Suven Life Sciences Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -34.31 % year-on-year, although there was a slight dip of -37.43 % from the previous quarter. Expenses decreased by -16.1 % compared to the previous year, with a decrease of -25.5 % quarter-on-quarter. Operating Profit surged by 15.13 % annually, and saw a 24.92 % increase from the last quarter.
Net Profit showed yearly increase of 6.34 %, and experienced a 21.19 % increase from the previous quarter. Earnings Per Share (EPS) rose by 6.77 % annually, however rose by 21.15 % compared to the last quarter. In essence, while Suven Life Sciences Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.

Join our telegram for more updates

Stay Updated with Our YouTube Videos

Related Post